BRUIN CLL-322 is the first Phase 3 study to demonstrate superiority over a venetoclax-containing control arm in CLL, and, with the majority of patients...
NYSE issues a pre-market daily advisory direct from the trading floor.NEW YORK, June 12, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides...
NYSE issues a pre-market daily advisory direct from the trading floor.NEW YORK, June 4, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides...
NYSE issues a pre-market daily advisory direct from the trading floor.NEW YORK, June 4, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides...
NYSE issues a pre-market daily advisory direct from the trading floor.NEW YORK, June 4, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides...